Management of Dyslipidemia in Adults

Initial Assessment & Risk Stratification

• Obtain a fasting lipid panel (total cholesterol, LDL‑C, HDL‑C, triglycerides) at diagnosis, before starting therapy, and repeat annually while on treatment. 1
• In adults < 40 years not receiving lipid‑lowering drugs, repeat the lipid panel at least every 5 years or sooner if new risk factors appear. 1
• Calculate 10‑year ASCVD risk with the Pooled Cohort Equations for patients without diabetes or established ASCVD to guide treatment intensity. 2

Lifestyle Modifications (Foundation for All Patients)

• Adopt a Mediterranean or DASH dietary pattern rich in vegetables, fruits, whole grains, legumes, and non‑tropical vegetable oils. 3, 1, 4
• Limit saturated fat to < 7 % of total calories and eliminate trans fats completely. 3, 2
• Increase intake of viscous fiber (≈10‑25 g/day), plant stanols/sterols (≈2 g/day), and omega‑3 fatty acids. 3, 4
• Perform ≥150 minutes/week of moderate‑intensity aerobic activity (or ≥75 minutes/week of vigorous activity). 2
• Pursue weight loss when overweight or obese. 3, 4

Statin Therapy

Primary Prevention – Patients with Diabetes

• Age 40‑75 y with diabetes + ≥ 1 additional ASCVD risk factor (e.g., hypertension, smoking, CKD, albuminuria, premature family history): start high‑intensity statin to achieve ≥50 % LDL‑C reduction and target LDL‑C < 70 mg/dL. 3, 1, 4
• High‑intensity options: atorvastatin 40‑80 mg daily or rosuvastatin 20‑40 mg daily. 3, 5
• Age 40‑75 y with diabetes + no additional ASCVD risk factors: use moderate‑intensity statin. 6, 5
• Moderate‑intensity options: atorvastatin 10‑20 mg, rosuvastatin 5‑10 mg, simvastatin 20‑40 mg, or pravastatin 40‑80 mg daily. 6, 5
• Age 20‑39 y with diabetes + additional ASCVD risk factors: consider statin after shared decision‑making. 3, 4
• Age > 75 y with diabetes: continue current statin if already on therapy; if initiating, consider moderate‑intensity statin after shared decision‑making. 3, 1, 4

Primary Prevention – Patients without Diabetes

• LDL‑C ≥ 190 mg/dL (≥ 4.9 mmol/L): initiate high‑intensity statin immediately, aiming for ≥50 % LDL‑C reduction regardless of age or calculated risk. 2
• 10‑year ASCVD risk 7.5 %–<20 % (intermediate risk): start moderate‑intensity statin; upgrade to high‑intensity if risk‑enhancing factors (e.g., premature CHD family history, CKD, metabolic syndrome, triglycerides ≥ 175 mg/dL, inflammatory disease) are present. 2
• 10‑year ASCVD risk ≥ 20 % (high risk): use high‑intensity statin to achieve ≥50 % LDL‑C reduction. 2
• 10‑year ASCVD risk 5 %–<7.5 % (borderline risk): consider moderate‑intensity statin only if risk‑enhancing factors exist; coronary artery calcium score ≥ 100 (or ≥ 75th percentile) may justify statin initiation. 2

Secondary Prevention – Established ASCVD

• All ages with documented ASCVD: prescribe high‑intensity statin (atorvastatin 40‑80 mg or rosuvastatin 20‑40 mg daily) irrespective of baseline LDL‑C. 3, 6, 5
• Target LDL‑C < 70 mg/dL and ≥50 % reduction from baseline. 3, 1
• If high‑intensity statin is not tolerated, maintain the maximum tolerated statin dose rather than discontinuing therapy. 6, 5

Non‑Statin Lipid‑Lowering Add‑On Therapies

Ezetimibe (First‑Line Add‑On)

• Add ezetimibe 10 mg daily when LDL‑C remains ≥ 70 mg/dL on maximally tolerated statin in diabetic patients aged 40‑75 y at higher cardiovascular risk. 3, 4
• Add ezetimibe when LDL‑C ≥ 70 mg/dL on maximally tolerated statin in patients with established ASCVD (very high risk). 6, 5
• Add ezetimibe when 10‑year ASCVD risk ≥ 20 % and LDL‑C reduction < 50 % on maximally tolerated statin. 6

PCSK9 Inhibitors (Second‑Line Add‑On)

• Add a PCSK9 inhibitor (evolocumab or alirocumab) when LDL‑C ≥ 70 mg/dL despite maximally tolerated statin + ezetimibe in very high‑risk patients with established ASCVD. 3, 6, 5
• Add a PCSK9 inhibitor for diabetic patients aged 40‑75 y with multiple ASCVD risk factors whose LDL‑C remains ≥ 70 mg/dL on maximally tolerated statin. 3, 4

Bempedoic Acid (Statin‑Intolerant Patients)

• For statin‑intolerant diabetic patients, use bempedoic acid as an alternative cholesterol‑lowering agent to reduce cardiovascular events. 3, 4
• PCSK9‑inhibitor monoclonal antibodies or inclisiran siRNA may also be considered in statin‑intolerant individuals. 1

Management of Elevated Triglycerides

• For triglycerides ≥ 150 mg/dL (≥ 1.7 mmol/L) and/or low HDL‑C, first intensify lifestyle therapy and optimize glycemic control. 3, 1, 4
• HDL‑C thresholds defining low HDL: < 40 mg/dL (< 1.0 mmol/L) in men, < 50 mg/dL (< 1.3 mmol/L) in women. 3, 4

Monitoring Strategy

• Re‑measure the lipid panel 4‑12 weeks after initiating or changing any statin or lipid‑lowering therapy to verify response and adherence. 3, 6, 1, 5
• Perform annual lipid monitoring once the regimen is stable. 3, 1

Special Populations

• Age > 75 y – Continue existing statin if well‑tolerated; for new initiation, consider moderate‑intensity statin after shared decision‑making. 3, 6, 1, 5, 4
• Pregnancy – Statin therapy is contraindicated. 3, 4, 5

Clinical Pitfalls to Avoid

• Do not base statin intensity in diabetic patients aged 40‑75 y solely on baseline LDL‑C; incorporate the presence of additional ASCVD risk factors. 3, 1
• Do not discontinue statins because of intolerance without first trying alternative statins, lower doses, or intermittent dosing schedules. 1

Hyperlipidemia Management

Initial Assessment and Risk Stratification

• The American Diabetes Association recommends that all patients with hyperlipidemia should begin with lifestyle modifications and statin therapy, with the intensity determined by cardiovascular risk and presence of atherosclerotic cardiovascular disease (ASCVD) 7
• The American Diabetes Association suggests measuring fasting lipid profile including total cholesterol, LDL-C, HDL-C, and triglycerides at diagnosis and before initiating therapy, with repeat lipid panels every 5 years or more frequently if indicated for adults under 40 years not on lipid-lowering therapy 7, 8

Lifestyle Modifications

• The American Heart Association recommends adopting a Mediterranean-style or DASH eating pattern emphasizing vegetables, fruits, whole grains, legumes, low-fat protein sources, and nontropical vegetable oils, and reducing saturated fat to <7% of total calories and eliminating trans fats 7, 9
• The American College of Cardiology recommends increasing dietary omega-3 fatty acids, viscous fiber (>10 g/day), and plant stanols/sterols, and limiting sweets, sugar-sweetened beverages, and red meats 7, 9
• The American Diabetes Association suggests engaging in aerobic exercise 3-4 sessions per week, 40 minutes per session on average, at moderate-to-vigorous intensity, and aiming for at least 150 minutes of physical activity weekly 10, 11

Pharmacological Therapy

• The American College of Cardiology recommends initiating moderate-intensity statin therapy (atorvastatin 10-20 mg or rosuvastatin 5-10 mg daily) in addition to lifestyle modifications for patients aged 40-75 years without ASCVD, and high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for patients with established ASCVD 7, 11, 12
• The European Society of Cardiology recommends targeting LDL-C <70 mg/dL (1.8 mmol/L) or at least 50% reduction from baseline for patients with established ASCVD, and LDL-C <55 mg/dL (1.4 mmol/L) for very high-risk patients 13, 14

Adding Ezetimibe to Statin Therapy

• The American Diabetes Association recommends adding ezetimibe 10 mg daily to achieve additional 15-25% LDL-C reduction when LDL-C remains ≥70 mg/dL on maximally tolerated statin therapy in high-risk or very high-risk patients 7, 12
• The European Heart Journal suggests that ezetimibe may be preferred over PCSK9 inhibitors due to lower cost when both are options 8

Alternative and Adjunctive Therapies

• The American Diabetes Association recommends intensifying lifestyle therapy and optimizing glycemic control in diabetic patients with elevated triglycerides (≥150 mg/dL), and considering fenofibrate or icosapent ethyl for additional triglyceride reduction 7, 10
• The American College of Cardiology suggests prioritizing lifestyle modifications, including exercise and smoking cessation, for patients with low HDL-C (<40 mg/dL men, <50 mg/dL women), and considering gemfibrozil or niacin if HDL-C remains low 7, 9, 15

Monitoring Strategy

• The American Diabetes Association recommends assessing lipid panel 4-12 weeks after initiating or changing therapy to estimate efficacy and adherence, and monitoring annually once stable on therapy 7, 8, 11
• The American College of Cardiology suggests expecting approximately 1% ASCVD risk reduction for every 1% LDL-C reduction achieved, and demonstrating 9% reduction in all-cause mortality and 13% reduction in vascular mortality for each 39 mg/dL (1 mmol/L) reduction in LDL-C 7, 11

ACC Evidence‑Based Dyslipidemia Management Guidelines

Risk Assessment and Statin Initiation

• The American College of Cardiology (ACC) recommends that all adults aged 40–75 years with diabetes receive at least moderate‑intensity statin therapy regardless of baseline LDL‑C or 10‑year ASCVD risk (Class I, Level A) 16.
• For non‑diabetic adults aged 40–75 years, the ACC advises calculation of the 10‑year ASCVD risk using the Pooled Cohort Equations before deciding on therapy 16.
• When the 10‑year ASCVD risk is ≥20 %, initiate a high‑intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) aiming for ≥50 % LDL‑C reduction (Class I, Level A) 16.
• If the risk is 7.5–<20 %, start a moderate‑to‑high‑intensity statin and upgrade to high‑intensity if any risk‑enhancing factor is present (e.g., premature family history of CHD, chronic kidney disease, metabolic syndrome, triglycerides ≥175 mg/dL, inflammatory disease) (Class I, Level A) 16.
• For a risk of 5–<7.5 %, consider a moderate‑intensity statin only when risk‑enhancing factors exist; a coronary artery calcium score ≥100 or ≥75th percentile may also justify initiation (Class I, Level A) 16.
• When the risk is <5 %, lifestyle modification alone is recommended; pharmacologic therapy is generally not indicated (Class I, Level A) 16.
• Adults aged 20–75 years with LDL‑C ≥190 mg/dL (≥4.9 mmol/L) should receive high‑intensity statin therapy immediately without ASCVD risk calculation, targeting ≥50 % LDL‑C reduction (Class I, Level A) 16.
• In secondary prevention (established ASCVD), the ACC mandates high‑intensity statin therapy for all ages, with a target LDL‑C <70 mg/dL and ≥50 % reduction; if high‑intensity is not tolerated, the maximum tolerated dose should be continued (Class I, Level A) 16.

Lifestyle Recommendations

• Adopt a Mediterranean or DASH dietary pattern rich in vegetables, fruits, whole grains, legumes, low‑fat protein sources, and non‑tropical vegetable oils (Class IIa, Level B) 17.
• Limit saturated fat to <7 % of total calories and eliminate trans fats (Class IIa, Level B) 16, 17.
• Perform ≥150 minutes/week of moderate‑intensity aerobic activity (or ≥75 minutes/week of vigorous activity) (Class IIa, Level B) 17.
• Include resistance training (≥2 sessions/week, 3 sets of 8–12 repetitions at 60–80 % of 1‑RM) (Class IIa, Level B) 17.
• Achieve 5–10 % body‑weight loss in overweight/obese individuals to obtain an approximate 20 % reduction in triglycerides (Class IIa, Level B) 17.
• Provide smoking‑cessation counseling combined with nicotine replacement, varenicline, and/or bupropion as appropriate (Class IIa, Level B) 17.

Statin Intensity and Dosing

• High‑intensity statins (≥50 % LDL‑C reduction):
  
  • Atorvastatin 40–80 mg daily (Class I, Level A) 16
  • Rosuvastatin 20–40 mg daily (Class I, Level A) 16
• Moderate‑intensity statins (30–49 % LDL‑C reduction):
  
  • Atorvastatin 10–20 mg daily (Class I, Level A) 16
  • Rosuvastatin 5–10 mg daily (Class I, Level A) 16
  • Simvastatin 20–40 mg daily (Class I, Level A) 16
  • Pravastatin 40–80 mg daily (Class I, Level A) 16

Non‑Statin Add‑On Therapies

• Ezetimibe 10 mg daily should be added when LDL‑C remains ≥70 mg/dL on maximally tolerated statin in any of the following groups:
  
  • Diabetic patients aged 40–75 years at higher cardiovascular risk (Class IIa, Level B)
  • Patients with established ASCVD (very high risk) (Class IIa, Level B)
  • Individuals with a 10‑year ASCVD risk ≥20 % who achieve <50 % LDL‑C reduction on maximally tolerated statin (Class IIa, Level B) 16.
• PCSK9 inhibitors (evolocumab or alirocumab) are recommended when LDL‑C ≥70 mg/dL persists despite maximally tolerated statin + ezetimibe in:
  
  • Very high‑risk patients with established ASCVD (Class IIa, Level B)
  • Diabetic patients aged 40–75 years with multiple ASCVD risk factors (Class IIa, Level B)
  • Adults aged 30–75 years with heterozygous familial hypercholesterolemia and LDL‑C ≥100 mg/dL on maximally tolerated statin + ezetimibe (Class IIa, Level B) 16.

Monitoring and Follow‑up

• Obtain a fasting lipid panel at diagnosis, before initiating therapy, and annually thereafter while on treatment (Class I, Level B) – citation not required per source.
• Repeat the lipid panel 4–12 weeks after any initiation or change in statin or other lipid‑lowering therapy to assess response and adherence (Class I, Level A) 16.

Special Considerations for Adults >75 Years

• For patients already on statin therapy, continue the current regimen if it is well‑tolerated (Class I, Level A) 16.

All statements are derived from ACC guideline recommendations and reflect the cited evidence levels where provided.